David Goldstein, who is director of the Institute for Genomic Medicine at the Columbia University Medical Centre, is to advise AstraZeneca Plc on its plan to integrate genomics into the company’s global research and development strategy. Professor Goldstein will continue in his full-time role at Columbia, while also acting as chief adviser to the AstraZeneca project, which is expected to be carried out over 10 years.
AstraZeneca announced the appointment on 28 September 2016.
Copyright 2016 Evernow Publishing Ltd